Today I am in anticipation of a miracle. But until I don't open this secret ... Just pray for me ...
My name is Monika Lemeshonok, I am painter from Belarus. From born I have rare disease of the spinal cord - Spinal Muscular Atrophy Type 2. From this disease, I can’t walk and move, I'm in a wheelchair. But I love life and around the world. I express my love for life through painting artwork, I have art exhibitions throughout Europe and many art lovers appreciate my works.
Monday, May 22, 2017
Thursday, May 18, 2017
Plans for treatment in Bologna
I did not write here for several days because I had a cold, I had fever and sore throat. But today I feel better and can write the results of my trip to Bologna and talk about plans for the future.
In the clinic I got a full medical examination, it showed that I was in good physical condition. I underwent nocturnal oximetry (measurement of oxygen in the lungs) and the result was very good, and also good spirometry and echocardiography. I got a recommendation on how to use the cough machine correctly and now I'm training the lungs with this device every day.
Now I will talk about future plans for treatment. Dr. Villanova said that I must arrive every year to the clinic Nigrisoli for medical examination, this is necessary to support my health and the state of my respiratory system. But for treatment in Bologna I need money for air tickets for there and back way for three people: for me, my mother and my grandmother, because they help me on the trip. I ask to help me again in this! I need 2000 € for buying air tickets for treatment in Bologna which is planned for spring next year. Please tell your friends about this and make a repost of this message.
In the clinic I got a full medical examination, it showed that I was in good physical condition. I underwent nocturnal oximetry (measurement of oxygen in the lungs) and the result was very good, and also good spirometry and echocardiography. I got a recommendation on how to use the cough machine correctly and now I'm training the lungs with this device every day.
Now I will talk about future plans for treatment. Dr. Villanova said that I must arrive every year to the clinic Nigrisoli for medical examination, this is necessary to support my health and the state of my respiratory system. But for treatment in Bologna I need money for air tickets for there and back way for three people: for me, my mother and my grandmother, because they help me on the trip. I ask to help me again in this! I need 2000 € for buying air tickets for treatment in Bologna which is planned for spring next year. Please tell your friends about this and make a repost of this message.
https://www.facebook.com/photo.php?fbid=249886932082321&set=gm.1376656052425065&type=3&theater
Monday, May 15, 2017
I am near SMA clinic Nigrisoli
I am near SMA clinic Nigrisoli with my mother and grandmother in Bologna, Italy.
Friday, May 12, 2017
I am visited in SMA clinic Nigrisoli
I am with Doc. Villanova in clinic Nigrisoli.
Yesterday I returned at home from my treatment. I was 10 days on treatment in clinic Nigrisoli in Bologna (Italy). Every day I had a medical examination. On the first day, I had an x-ray of the spine and echocardiography, on the second day I had night ossimetry (measurement of oxygen in the blood), on the third day I had a blood test and respiratory treatment using a cough machine. All the results of my survey are very good! I am very happy.
I am very happy that a wheelchair was made for me !!! This wheelchair is very comfortable for me and helps to pull my spine.
Thank you very much for Dr. Villanova and Signor Luciano Braconi for this help!!! And also I want say Many Thanks to «Fondazione "Aiutiamoli a Vivere", Luca Avogadro, Cristina Coli, Serena Braconi and ALL my italiano friends for help with my treatment and organization trip in Bologna.
Many THANKS ALL!
Yesterday I returned at home from my treatment. I was 10 days on treatment in clinic Nigrisoli in Bologna (Italy). Every day I had a medical examination. On the first day, I had an x-ray of the spine and echocardiography, on the second day I had night ossimetry (measurement of oxygen in the blood), on the third day I had a blood test and respiratory treatment using a cough machine. All the results of my survey are very good! I am very happy.
I am very happy that a wheelchair was made for me !!! This wheelchair is very comfortable for me and helps to pull my spine.
Thank you very much for Dr. Villanova and Signor Luciano Braconi for this help!!! And also I want say Many Thanks to «Fondazione "Aiutiamoli a Vivere", Luca Avogadro, Cristina Coli, Serena Braconi and ALL my italiano friends for help with my treatment and organization trip in Bologna.
Many THANKS ALL!
Wednesday, April 26, 2017
In soon I will going to treatment
It remains 4 days before my trip to Bologna for treatment. I'm worried because not all things have been collected and there are no tickets for the train from Milan to Bologna. But I hope everything will be fine.
Friday, April 7, 2017
AveXis’ AVXS-101 Shows Promise in Treating Infants with SMA Type 1
The Phase 1 study (NCT02122952) investigated the effects of AVXS-101 treatment by intravenous injection in 15 infants with SMA type 1 who were six months old or younger. Two doses were compared, the lower dose for Cohort 1 with three patients, and the higher dose for Cohort 2 with 12 patients.
The treatment’s short-term safety was evaluated over a two-year period, but a follow-up safety analysis will be carried out when the last patient reaches 2 years of age post-treatment. Patients will then be monitored annually as per standard of care for up to 15 years.
The endpoints measured were the time from birth to an “event” (death or at least 16 hours of daily ventilation support for 14 consecutive days in the absence of acute reversible illness or perioperatively) and the ability to sit independently, confirmed by video. Researchers also assessed patients with a standard motor milestone development survey and the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND).
An interim data analysis, released lasted year, revealed a favorable safety profile with no new treatment-related safety or tolerability concerns identified. Motor skill improvements were also observed, especially in children treated with the higher dose.
As of Jan. 20, 2017, AVXS-101 maintains its safety profile and was well-tolerated by the patients. Indeed, 12 out of 12 patients (100%) who received the highest one-time therapeutic dose of AVXS-101 (Cohort 2) reached 13.6 months of age without events reported. Of note, the expected event-free survival rate for this disease is 25%.
Results also showed that 11 patients (92%) in this cohort achieved head control, nine patients (75%) were able to roll a minimum of 180 degrees from back to both left and right, and 11 patients (92%) could sit without help.
After the treatment, AveXis used three different measures to evaluate unassisted sitting with increasing amounts of time. Results showed that nine of 12 patients (75%) sat unassisted for five seconds, seven (58%) sat for at least 10 seconds, and five patients (42%) sat for 30 seconds or more. Also, two patients could walk independently, besides having achieved other milestones, including standing with support, standing alone, and walking with support.
In addition, as of Jan. 20, 2017, nine of nine patients (three in the low-dose cohort and six in Cohort 2) — reached 20 months without reported events. Here, the expected event-free rate is 8%.
“The completion of our Phase 1 clinical study of AVXS-101, the first ever gene therapy studied for the treatment of SMA type 1, is an exciting and eagerly awaited milestone, and we are quite pleased with these data,” Sean Nolan, AveXis’ president and CEO, said in a news release.
“The past few months have been productive for AveXis, and we look forward to continuing the momentum with several upcoming corporate catalysts … as well as ongoing collaborative discussions with regulatory authorities in the United States and Europe to explore the most expeditious pathways for marketing approval of AVXS-101,” Noland added.
The treatment’s short-term safety was evaluated over a two-year period, but a follow-up safety analysis will be carried out when the last patient reaches 2 years of age post-treatment. Patients will then be monitored annually as per standard of care for up to 15 years.
The endpoints measured were the time from birth to an “event” (death or at least 16 hours of daily ventilation support for 14 consecutive days in the absence of acute reversible illness or perioperatively) and the ability to sit independently, confirmed by video. Researchers also assessed patients with a standard motor milestone development survey and the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND).
An interim data analysis, released lasted year, revealed a favorable safety profile with no new treatment-related safety or tolerability concerns identified. Motor skill improvements were also observed, especially in children treated with the higher dose.
As of Jan. 20, 2017, AVXS-101 maintains its safety profile and was well-tolerated by the patients. Indeed, 12 out of 12 patients (100%) who received the highest one-time therapeutic dose of AVXS-101 (Cohort 2) reached 13.6 months of age without events reported. Of note, the expected event-free survival rate for this disease is 25%.
Results also showed that 11 patients (92%) in this cohort achieved head control, nine patients (75%) were able to roll a minimum of 180 degrees from back to both left and right, and 11 patients (92%) could sit without help.
After the treatment, AveXis used three different measures to evaluate unassisted sitting with increasing amounts of time. Results showed that nine of 12 patients (75%) sat unassisted for five seconds, seven (58%) sat for at least 10 seconds, and five patients (42%) sat for 30 seconds or more. Also, two patients could walk independently, besides having achieved other milestones, including standing with support, standing alone, and walking with support.
In addition, as of Jan. 20, 2017, nine of nine patients (three in the low-dose cohort and six in Cohort 2) — reached 20 months without reported events. Here, the expected event-free rate is 8%.
“The completion of our Phase 1 clinical study of AVXS-101, the first ever gene therapy studied for the treatment of SMA type 1, is an exciting and eagerly awaited milestone, and we are quite pleased with these data,” Sean Nolan, AveXis’ president and CEO, said in a news release.
“The past few months have been productive for AveXis, and we look forward to continuing the momentum with several upcoming corporate catalysts … as well as ongoing collaborative discussions with regulatory authorities in the United States and Europe to explore the most expeditious pathways for marketing approval of AVXS-101,” Noland added.
Text from: https://smanewstoday.com/2017/04/06/avexis-avxs-101-shows-promise-treatment-infants-sma-type-1/
Subscribe to:
Posts (Atom)